Glaucoma 360 New Horizons Forum
Glaucoma 360 New Horizons Forum
February 17, 2020
1 min watch
Save

VIDEO: Novel drug aims to lower episcleral venous pressure to treat glaucoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thurein Htoo, MS, MBA, CEO of Qlaris Bio, discusses how the company is targeting episcleral venous pressure in the treatment of glaucoma. QLS-101, Qlaris Bio’s novel topical drug therapy, acts to reduce episcleral venous pressure, therefore reducing IOP.

Glaucoma 360 attendees voted Htoo’s presentation the winner of the Best Pitch Award.